HRP20200898T1 - Vodeni farmaceutski pripravak tapentadola za oralnu primjenu - Google Patents
Vodeni farmaceutski pripravak tapentadola za oralnu primjenu Download PDFInfo
- Publication number
- HRP20200898T1 HRP20200898T1 HRP20200898TT HRP20200898T HRP20200898T1 HR P20200898 T1 HRP20200898 T1 HR P20200898T1 HR P20200898T T HRP20200898T T HR P20200898TT HR P20200898 T HRP20200898 T HR P20200898T HR P20200898 T1 HRP20200898 T1 HR P20200898T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- tapentadol
- pharmaceutical
- dosage form
- preservative
- Prior art date
Links
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 title claims 5
- 229960005126 tapentadol Drugs 0.000 title claims 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 239000002552 dosage form Substances 0.000 claims 5
- 239000003755 preservative agent Substances 0.000 claims 5
- 230000002335 preservative effect Effects 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 claims 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 claims 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 claims 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 1
- 229960001950 benzethonium chloride Drugs 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 229960004365 benzoic acid Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 229960003168 bronopol Drugs 0.000 claims 1
- 229940067596 butylparaben Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960002798 cetrimide Drugs 0.000 claims 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 1
- 229960003260 chlorhexidine Drugs 0.000 claims 1
- 229960004926 chlorobutanol Drugs 0.000 claims 1
- 229960002242 chlorocresol Drugs 0.000 claims 1
- 229960005443 chloroxylenol Drugs 0.000 claims 1
- 229930003836 cresol Natural products 0.000 claims 1
- 229940013361 cresol Drugs 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 229960004756 ethanol Drugs 0.000 claims 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 229960004867 hexetidine Drugs 0.000 claims 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 claims 1
- 229940113174 imidurea Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960003742 phenol Drugs 0.000 claims 1
- 229960005323 phenoxyethanol Drugs 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 229940067107 phenylethyl alcohol Drugs 0.000 claims 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 claims 1
- 235000010241 potassium sorbate Nutrition 0.000 claims 1
- 239000004302 potassium sorbate Substances 0.000 claims 1
- 229940069338 potassium sorbate Drugs 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims 1
- 235000010234 sodium benzoate Nutrition 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 229960003885 sodium benzoate Drugs 0.000 claims 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 claims 1
- 235000010334 sodium propionate Nutrition 0.000 claims 1
- 239000004324 sodium propionate Substances 0.000 claims 1
- 229960003212 sodium propionate Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- -1 thymesal Chemical compound 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (13)
1. Vodeni farmaceutski pripravak koji sadrži tapentadol ili njegovu fiziološki prihvatljivu sol i prilagođen je za oralnu primjenu, pri čemu pripravak dodatno sadrži konzervans, pri čemu je sadržaj konzervansa najviše 90% sadržaja koji bi bio potreban u skladu s Ph .Eur. da bi se dovoljno očuvalo farmaceutski pripravak u nedostatku tapentadola.
2. Pripravak prema zahtjevu 1, naznačen time, da
(i) dodatno sadrži međuspremnik; i / ili
(ii) ima pH vrijednost u rasponu od 3,0 do 6,5.
3. Pripravak prema zahtjevu 1 ili 2, naznačen time, da je koncentracija tapentadola jednaka ili manja od 50 mg / ml, na temelju ukupnog volumena pripravaka.
4. Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da je konzervans izabran iz grupe koju čine benzalkonijev klorid, benzetonijev klorid, benzojeva kiselina, natrijev benzoat, benzil alkohol, bronopol, cetrimid, cetilpiridinijev klorid, klorheksidin, klorbutanol, klorokrezol, kloroksilenol, krezol, etilni alkohol, glicerin, heksetidin, imidurea, fenol, fenoksietanol, feniletil alkohol, fenilmerkurijski nitrat, propilen glikol, natrijev propionat, timesal, metil paraben, etil paraben, propil paraben, butil paraben, izobutil paraben, benzil kiselina i kalijev sorbat.
5. Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da je sadržaj konzervansa najviše 5,0 tež .-%, u odnosu na ukupnu težinu pripravka.
6. Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da je zbroj koncentracije tapentadola i koncentracije konzervansa jednak ili manji od 50 mg / ml, u odnosu na ukupni volumen pripravka.
7. Pripravak prema bilo kojem od prethodnih zahtjeva, koji pokazuje rok trajanja u ubrzanim uvjetima skladištenja od najmanje 3 mjeseca.
8. Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time što je izabran iz skupine koja se sastoji od sirupa, kapi, otopina, disperzija, suspenzija i emulzija.
9. Farmaceutski oblik doziranja koji sadrži farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 8.
10. Oblik doziranja u skladu s patentnim zahtjevom 9, naznačen time što je izabran iz skupine koja se sastoji od oralnih otopina, oralnih gelova, suspenzija, emulzija i kapsula napunjenih tekućinom ili gelom.
11. Oblik doziranja u skladu s patentnim zahtjevom 9 ili 10, naznačen time što je prilagođen za primjenu pedijatrijskim pacijentima.
12. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 8 ili farmaceutski oblik doziranja prema bilo kojem od zahtjeva 9 do 11, naznačen time, da se upotrebljava za liječenje boli.
13. Farmaceutski pripravak ili farmaceutski oblik doziranja u skladu s patentnim zahtjevom 12, naznačen time što je bol izabrana iz skupine koja se sastoji od akutne i kronične boli.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161449287P | 2011-03-04 | 2011-03-04 | |
EP11003601 | 2011-05-03 | ||
EP17189271.4A EP3287123B1 (en) | 2011-03-04 | 2012-03-02 | Aqueous pharmaceutical formulation of tapentadol for oral administration |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200898T1 true HRP20200898T1 (hr) | 2020-10-02 |
Family
ID=44650617
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191777TT HRP20191777T1 (hr) | 2011-03-04 | 2019-10-01 | Vodena farmaceutska formulacija tapentadola za oralnu primjenu |
HRP20200898TT HRP20200898T1 (hr) | 2011-03-04 | 2020-06-04 | Vodeni farmaceutski pripravak tapentadola za oralnu primjenu |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191777TT HRP20191777T1 (hr) | 2011-03-04 | 2019-10-01 | Vodena farmaceutska formulacija tapentadola za oralnu primjenu |
Country Status (23)
Country | Link |
---|---|
US (3) | US20130022670A1 (hr) |
EP (4) | EP3597182A1 (hr) |
JP (3) | JP6046057B2 (hr) |
KR (2) | KR101946790B1 (hr) |
CN (2) | CN107308108A (hr) |
AU (2) | AU2012224952C1 (hr) |
BR (1) | BR112013022495A2 (hr) |
CA (1) | CA2828631C (hr) |
CY (2) | CY1125100T1 (hr) |
DK (2) | DK3287123T3 (hr) |
EA (2) | EA027290B1 (hr) |
ES (1) | ES2756776T3 (hr) |
HR (2) | HRP20191777T1 (hr) |
HU (1) | HUE046557T2 (hr) |
IL (2) | IL227824B (hr) |
LT (2) | LT2680832T (hr) |
MX (2) | MX369121B (hr) |
PL (2) | PL3287123T3 (hr) |
PT (2) | PT3287123T (hr) |
RS (2) | RS59491B1 (hr) |
SI (2) | SI2680832T1 (hr) |
WO (1) | WO2012119727A1 (hr) |
ZA (1) | ZA201306478B (hr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
KR101616246B1 (ko) | 2008-01-25 | 2016-05-02 | 그뤼넨탈 게엠베하 | 약제학적 투여형 |
MX2010012039A (es) | 2008-05-09 | 2010-11-30 | Gruenenthal Gmbh | Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio. |
MX2012000317A (es) | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Forma de dosificacion de liberacion controlada extruida por fusion en caliente. |
RU2015138422A (ru) | 2009-07-22 | 2018-12-25 | Грюненталь Гмбх | Стабильная при окислении, прочная на излом лекарственная форма |
ES2487244T3 (es) | 2010-09-02 | 2014-08-20 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación que comprende un polímero aniónico |
CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
PL3287123T3 (pl) | 2011-03-04 | 2020-11-02 | Grünenthal GmbH | Wodny preparat farmaceutyczny tapentadolu do podawania doustnego |
ES2712072T3 (es) * | 2011-07-20 | 2019-05-09 | Torrent Pharmaceuticals Ltd | Composición farmacéutica de tapentadol |
AU2012292418B2 (en) | 2011-07-29 | 2017-02-16 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
CA2839123A1 (en) | 2011-07-29 | 2013-02-07 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
MX356421B (es) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico. |
CN104394851B (zh) | 2012-04-18 | 2017-12-01 | 格吕伦塔尔有限公司 | 抗篡改和抗剂量‑倾泻药物剂型 |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
AR096438A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
BR112016000194A8 (pt) | 2013-07-12 | 2019-12-31 | Gruenenthal Gmbh | forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila |
EP2845625A1 (en) | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
WO2015173195A1 (en) * | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
JP2017516789A (ja) | 2014-05-26 | 2017-06-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エタノール過量放出に対して防護されている多粒子 |
PT3273953T (pt) * | 2015-03-27 | 2019-04-01 | Gruenenthal Gmbh | Formulação estável para administração parentérica de tapentadol |
EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
CN105997862A (zh) * | 2016-07-15 | 2016-10-12 | 蓝佳堂生物医药(福建)有限公司 | 一种口腔溃疡含漱液及其制备方法 |
WO2018055070A1 (en) * | 2016-09-23 | 2018-03-29 | Grünenthal GmbH | Stable formulation for parenteral administration of tapentadol |
EP3585370A1 (en) | 2017-02-23 | 2020-01-01 | Grünenthal GmbH | Tapentadol as local anesthetic |
CN108434042A (zh) * | 2018-05-31 | 2018-08-24 | 武汉新大地环保材料股份有限公司 | 一种新型日化防腐剂及其制备方法 |
EP4011369A1 (en) * | 2020-12-14 | 2022-06-15 | G.L. Pharma GmbH | Aqueous pharmaceutical composition comprising tapentadol tartrate |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8334422D0 (en) | 1983-12-23 | 1984-02-01 | Sterwin Ag | Composition |
GB8334423D0 (en) | 1983-12-23 | 1984-02-01 | Sterwin Ag | Composition |
US4775678A (en) | 1984-10-01 | 1988-10-04 | Schering Corporation | Clotrimazole cream |
AU614465B2 (en) | 1989-04-05 | 1991-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
US6183758B1 (en) | 1998-01-29 | 2001-02-06 | Highland Laboratories, Inc. | Phytochemicals, nutrients & medication absorption &/or treatment |
US6211169B1 (en) | 1999-09-29 | 2001-04-03 | Aesgen, Inc. | Stable calcitriol solution for packaging into vials |
FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
US6594193B2 (en) * | 2000-06-22 | 2003-07-15 | Progressent Technologies, Inc. | Charge pump for negative differential resistance transistor |
US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
DE10109763A1 (de) * | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
US20050176790A1 (en) | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
DE10112325A1 (de) | 2001-03-13 | 2002-10-02 | Fresenius Kabi De Gmbh | Lagerstabile Fertiginfusionslösungen des Paracetamols |
JP4905616B2 (ja) | 2001-04-19 | 2012-03-28 | ライオン株式会社 | ソフトコンタクトレンズ用点眼剤 |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
FR2832063B1 (fr) | 2001-11-15 | 2004-08-27 | Aguettant Lab | Procede de production de solutions stables de substances phenoliques et les solutions en resultant |
CA2479350A1 (en) * | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
US20030191187A1 (en) | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
US20040101563A1 (en) * | 2002-07-18 | 2004-05-27 | Kundu Subhas C. | Storage stable antihistaminic syrup formulations |
AU2003275329B2 (en) * | 2002-09-13 | 2008-04-03 | Cydex Pharmaceuticals, Inc. | Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin |
US6888993B2 (en) | 2002-11-27 | 2005-05-03 | Corning Incorporated | Dispersion compensating optical fiber for SMF and transmission link including same |
ITMI20022748A1 (it) * | 2002-12-23 | 2004-06-24 | Eurand Int | Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione. |
SI1599222T1 (sl) | 2003-01-08 | 2009-08-31 | Novartis Vaccines & Diagnostic | Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja |
US20040180915A1 (en) | 2003-03-14 | 2004-09-16 | Xanodyne Pharmacal, Inc. | Methadone-containing compositions for parenteral administration and method of use thereof |
WO2005112926A1 (en) * | 2004-05-17 | 2005-12-01 | Pharmacofore, Inc. | Compositions and methods for treating or preventing pain |
SI1612203T1 (sl) | 2004-06-28 | 2007-12-31 | Gruenenthal Chemie | Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida |
AU2005259478B2 (en) | 2004-07-01 | 2010-07-15 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse containing (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
DE102004032103A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
KR20080026090A (ko) * | 2005-04-28 | 2008-03-24 | 테라퀘스트 바이오사이언시즈 엘엘씨 | 통증을 치료하기 위한 방법 및 조성물 |
TWI329334B (en) | 2005-12-02 | 2010-08-21 | Chung Shan Inst Of Science | Manufacture method of electromagnetic interference layer for the plasma display panel |
US20070166336A1 (en) * | 2005-12-13 | 2007-07-19 | David Delmarre | Stable and palatable oral liquid sumatriptan compositions |
US8176534B2 (en) | 2005-12-30 | 2012-05-08 | General Instrument Corporation | Method and apparatus for provisioning a device to access digital rights management (DRM) services in a universal plug and play (UPnP) network |
WO2007127158A2 (en) | 2006-04-25 | 2007-11-08 | Croda, Inc | Modification of percutaneous absorption of topically active materials |
EP2012764B1 (en) | 2006-04-28 | 2011-01-12 | Grünenthal GmbH | Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol |
PT2012763E (pt) | 2006-04-28 | 2011-04-29 | Gruenenthal Gmbh | Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine |
TWI401237B (zh) * | 2006-07-24 | 2013-07-11 | 3-〔(1r,2r)-3-(二甲基氨基)-1-乙基-2-甲基丙基〕酚之製備 | |
AU2007278224C1 (en) | 2006-07-24 | 2012-06-21 | Grünenthal GmbH | Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine |
EP1905440A1 (de) | 2006-09-06 | 2008-04-02 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen |
TWI394564B (zh) | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
DE102007012165A1 (de) * | 2007-03-12 | 2008-09-18 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes |
JP2008266168A (ja) | 2007-04-18 | 2008-11-06 | Teika Seiyaku Kk | 眼科用剤 |
EP1985292A1 (en) | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
EP1992334A1 (en) | 2007-05-08 | 2008-11-19 | Docpharma NV/SA | Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation |
US20090163451A1 (en) * | 2007-11-16 | 2009-06-25 | Frank Porreca | Methods for treating visceral pain |
CN104958282B (zh) | 2007-11-23 | 2018-05-29 | 格吕伦塔尔有限公司 | 他喷他多组合物 |
WO2009076236A2 (en) | 2007-12-06 | 2009-06-18 | Pain Therapeutics, Inc. | Micronized opioid compositions, formulations and dosage forms and methods of making same |
KR101616246B1 (ko) | 2008-01-25 | 2016-05-02 | 그뤼넨탈 게엠베하 | 약제학적 투여형 |
AU2008354622A1 (en) | 2008-04-08 | 2009-10-15 | Acino Pharma Ag | Aqueous pharmaceutical formulation |
AU2009340504A1 (en) * | 2008-10-30 | 2010-08-26 | Grunenthal Gmbh | Novel and potent tapentadol dosage forms |
JP2012514632A (ja) * | 2009-01-09 | 2012-06-28 | パナセア バイオテック リミテッド | 二段階放出型医薬懸濁剤 |
US20100227921A1 (en) * | 2009-03-03 | 2010-09-09 | Shire Llc | Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof |
EP2246044A1 (en) | 2009-04-21 | 2010-11-03 | Pierre Fabre Dermo-Cosmétique | Paediatric solutions comprising a beta-blocker |
US20100272815A1 (en) * | 2009-04-28 | 2010-10-28 | Actavis Group Ptc Ehf | Amorphous form of tapentadol hydrochloride |
NZ597763A (en) | 2009-07-27 | 2014-07-25 | Nocicepta Llc | Methods for treatment of pain |
WO2011016487A1 (ja) * | 2009-08-05 | 2011-02-10 | ナガセ医薬品株式会社 | インジゴカルミン製剤 |
WO2011071400A1 (en) | 2009-12-10 | 2011-06-16 | Tecnimede - Sociedade Técnico-Medicinal, S.A. | Method and composition for preparing stable liquid formulations of paracetamol |
WO2011083304A1 (en) | 2010-01-05 | 2011-07-14 | Shire Llc | Prodrugs of opioids and uses thereof |
EP2552486B1 (en) | 2010-03-30 | 2020-08-12 | Phosphagenics Limited | Transdermal delivery patch |
GB201006200D0 (en) | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
CN101948397A (zh) * | 2010-09-07 | 2011-01-19 | 天津泰普药品科技发展有限公司 | 镇痛药他喷他多重要中间体的制备方法 |
US20120270848A1 (en) | 2010-10-22 | 2012-10-25 | Galleon Pharmaceuticals, Inc. | Novel Compositions and Therapeutic Methods Using Same |
SI2680833T1 (sl) | 2011-03-04 | 2016-06-30 | Gruenenthal Gmbh | Parenteralno dajanje tapentadola |
PL3287123T3 (pl) | 2011-03-04 | 2020-11-02 | Grünenthal GmbH | Wodny preparat farmaceutyczny tapentadolu do podawania doustnego |
EP2680834B1 (en) | 2011-03-04 | 2017-10-18 | Grünenthal GmbH | Semisolid aqueous pharmaceutical composition containing tapentadol |
IN2012DE00912A (hr) | 2012-03-27 | 2015-09-11 | Fresenius Kabi Oncology Ltd | |
CN103159633B (zh) | 2012-07-06 | 2015-08-12 | 江苏恩华药业股份有限公司 | 他喷他多的制备方法及用于制备他喷他多的化合物 |
GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
CN103735500B (zh) | 2014-01-28 | 2016-01-20 | 江苏华泽医药科技有限公司 | 盐酸他喷他多注射液及其制备方法 |
PT3273953T (pt) | 2015-03-27 | 2019-04-01 | Gruenenthal Gmbh | Formulação estável para administração parentérica de tapentadol |
-
2012
- 2012-03-02 PL PL17189271T patent/PL3287123T3/pl unknown
- 2012-03-02 AU AU2012224952A patent/AU2012224952C1/en active Active
- 2012-03-02 MX MX2017007718A patent/MX369121B/es unknown
- 2012-03-02 ES ES12708672T patent/ES2756776T3/es active Active
- 2012-03-02 JP JP2013555796A patent/JP6046057B2/ja active Active
- 2012-03-02 RS RS20191382A patent/RS59491B1/sr unknown
- 2012-03-02 RS RS20200566A patent/RS60267B1/sr unknown
- 2012-03-02 LT LT12708672T patent/LT2680832T/lt unknown
- 2012-03-02 PL PL12708672T patent/PL2680832T3/pl unknown
- 2012-03-02 MX MX2013010101A patent/MX351584B/es active IP Right Grant
- 2012-03-02 DK DK17189271.4T patent/DK3287123T3/da active
- 2012-03-02 DK DK12708672.6T patent/DK2680832T3/da active
- 2012-03-02 CN CN201710605686.0A patent/CN107308108A/zh active Pending
- 2012-03-02 CN CN201280011672.1A patent/CN103501773A/zh active Pending
- 2012-03-02 PT PT171892714T patent/PT3287123T/pt unknown
- 2012-03-02 BR BR112013022495A patent/BR112013022495A2/pt not_active Application Discontinuation
- 2012-03-02 EP EP19187973.3A patent/EP3597182A1/en active Pending
- 2012-03-02 EA EA201300989A patent/EA027290B1/ru not_active IP Right Cessation
- 2012-03-02 CA CA2828631A patent/CA2828631C/en active Active
- 2012-03-02 EA EA201692443A patent/EA035750B1/ru not_active IP Right Cessation
- 2012-03-02 LT LTEP17189271.4T patent/LT3287123T/lt unknown
- 2012-03-02 PT PT127086726T patent/PT2680832T/pt unknown
- 2012-03-02 SI SI201231677T patent/SI2680832T1/sl unknown
- 2012-03-02 EP EP12708672.6A patent/EP2680832B1/en active Active
- 2012-03-02 SI SI201231778T patent/SI3287123T1/sl unknown
- 2012-03-02 US US13/410,768 patent/US20130022670A1/en not_active Abandoned
- 2012-03-02 EP EP20154395.6A patent/EP3685827A1/en active Pending
- 2012-03-02 HU HUE12708672A patent/HUE046557T2/hu unknown
- 2012-03-02 KR KR1020137026183A patent/KR101946790B1/ko active IP Right Grant
- 2012-03-02 KR KR1020197003032A patent/KR102051800B1/ko active IP Right Grant
- 2012-03-02 EP EP17189271.4A patent/EP3287123B1/en not_active Revoked
- 2012-03-02 WO PCT/EP2012/000904 patent/WO2012119727A1/en active Application Filing
-
2013
- 2013-08-06 IL IL227824A patent/IL227824B/en active IP Right Grant
- 2013-08-28 ZA ZA2013/06478A patent/ZA201306478B/en unknown
-
2016
- 2016-04-07 US US15/093,522 patent/US20160220516A1/en not_active Abandoned
- 2016-11-15 JP JP2016222084A patent/JP6437984B2/ja active Active
- 2016-12-13 AU AU2016273858A patent/AU2016273858B2/en active Active
-
2017
- 2017-10-02 IL IL254854A patent/IL254854B/en unknown
-
2018
- 2018-06-08 JP JP2018109967A patent/JP6735790B2/ja active Active
-
2019
- 2019-10-01 HR HRP20191777TT patent/HRP20191777T1/hr unknown
- 2019-10-10 CY CY20191101063T patent/CY1125100T1/el unknown
- 2019-10-24 US US16/662,392 patent/US11547678B2/en active Active
-
2020
- 2020-06-04 HR HRP20200898TT patent/HRP20200898T1/hr unknown
- 2020-06-04 CY CY20201100500T patent/CY1123023T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200898T1 (hr) | Vodeni farmaceutski pripravak tapentadola za oralnu primjenu | |
ES2911207T3 (es) | Composiciones de insulina de acción rápida | |
JP2017061521A5 (hr) | ||
Chua et al. | Plasma-Lyte 148 vs 0.9% saline for fluid resuscitation in diabetic ketoacidosis | |
ES2891983T3 (es) | Composiciones de insulina de acción rápida | |
Soergel et al. | Effect of antidiuretic hormone on human small intestinal water and solute transport | |
HRP20191994T1 (hr) | Formulacije ketorolaka spremne za uporabu | |
HRP20160400T1 (hr) | Parenteralna primjena tapentadola | |
ES2685667T3 (es) | Composición cosmética con principios activos para la reducción de las arrugas de la piel y/o para la reducción de la profundidad de los poros de la piel | |
JP2016539921A5 (hr) | ||
RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
JP2014510067A5 (hr) | ||
RU2008128418A (ru) | Композиция суспензии фексофенадина | |
RU2013111633A (ru) | Стабильная жидкая фармацевтическая композиция комплекса 3-(2,2,2-триметилгидразиний) пропионат-2-этил-6-метил-3-гидроксипиридина дисукцината, обладающая антигипоксическим, антиоксидантным и адаптогенным действием | |
US11744899B2 (en) | Pharmaceutical composition containing a hyaluronic acid derivative | |
van der Molen | Pathophysiology of contrast-induced acute kidney injury | |
US10940206B2 (en) | Ophthalmic composition comprising lipoic acid and a mucomimetic polymer | |
ES2961145T3 (es) | Composiciones farmacéuticas para la administración nasal de un compuesto de cobalamina | |
ES2873078T3 (es) | Jarabe para la tos que contiene hidrocloruro de ambroxol | |
ES2898387T3 (es) | Formulaciones altamente estables de hormona tiroidea en cápsulas blandas | |
CN104027304B (zh) | 胞磷胆碱钠葡萄糖注射液 | |
KR20140024862A (ko) | 히알루론산 또는 히알루론산염을 포함하는 수용액 | |
KR20140050593A (ko) | 히알루론산 또는 히알루론산염을 포함하는 수용액 | |
Kentner et al. | Small volume resuscitation with tempol is detrimental during uncontrolled hemorrhagic shock in rats | |
KR20140024863A (ko) | 히알루론산 또는 히알루론산염을 포함하는 수용액 |